ResearchMoz added Latest Research Report titled " Dengue Vaccine Market: Contribution of NGOs for Better Vaccine Access Expected to Drive the Market in Lower Income Countries: Global Industry Analysis & Opportunity Assessment, 2017 - 2027 " to it's Large Report database.
Global dengue vaccine market revenue is expected to expand at a significant rate owing to a large unmet need
The first dengue vaccine, Dengvaxia (CYD-TDV) developed by Sanofi Pasteur is registered in 14 countries in the Latin America and Asia Pacific region. CYD-TDV vaccine is a live recombinant tetravalent dengue vaccine that is indicated as a 3 dose series of 0/6/12 month schedule. There are around five other vaccine candidates under evaluation in clinical trials, comprising other live-attenuated vaccines as well as subunit, DNA and purified inactivated vaccine candidates of which Takedas TAK-003 and Butantan Institute vaccine candidates are being evaluated in phase 3 clinical trials currently.
The global dengue vaccine market is estimated to be valued at nearly US$ 250 Mn in 2017 and is expected to expand at a 17.5% CAGR over the forecast period (2017-2027). The global dengue vaccine market is projected to be valued at more than US$ 1250 Mn by 2027.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=1287933
Factors impacting the global dengue vaccine market
Growth of the global dengue vaccine market is mainly driven by rising burden of dengue fever in tropical regions, large unmet medical need for managing dengue burden, promising end stage vaccine pipeline, development of live attenuated tetravalent dengue vaccine, and expected local production of dengue vaccine in various countries. Other prominent factors driving revenue growth of the market are adoption/uptake of dengue vaccine by various countries in dengue endemic regions of Latin America and Asia Pacific and increased governmental interest to incorporate the vaccine in public immunisation programmes across various countries.
However, supply side infrastructure bottlenecks such as surveillance system, standardised diagnostics practice, and cold chain systems for storage of vaccine in resource constrained countries are the factors hampering the growth of the global dengue vaccine market.
Companies engaged in the development of dengue vaccine are employing strategies to incorporate dengue vaccine in public immunisation programmes and vaccines in clinical stage development are being tested for safety and efficacy in all age groups and different transmission settings.
Browse more details @ http://www.researchmoz.us/dengue-vaccine-market-contribution-of-ngos-for-better-vaccine-access-expected-to-drive-the-market-in-lower-income-countries-global-industry-analysis-and-opportunity-assessment-2017-2027-report.html
Table Of Content
1. Executive Summary
2. Market Introduction
2.1. Market Taxonomy
3. Global Dengue Vaccine Market Analysis Scenario
3.1. Market Size (US$ Mn) and Forecast
3.1.1. Market Size and Y-o-Y Growth
3.2.2. Absolute $ Opportunity
3.2. Market Overview
4. Market Dynamics and USPs
4.1. Macro-economic Factors
4.2. Drivers
4.2.1. Supply Side
4.2.2. Demand Side
4.3. Restraints
4.4. Opportunity
4.5. Trends
4.6. Dengue Vaccine Research Pipeline Analysis
4.7. Global Dengue Vaccine Market: Funding Scenario
4.8. Global Dengue Vaccine Market: Dengue Epidemiology Analysis
4.9. Global Dengue Vaccine Market: Dengvaxia SWOT
4.10. Global Dengue Vaccine Market: Dengvaxia Promotional Activities
4.11.Global Dengue Vaccine Market: Dengvaxia Sales Channel Strategy
4.12. Global Dengue Vaccine Market: Dengvaxia Tier-Pricing by Region
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
Global dengue vaccine market revenue is expected to expand at a significant rate owing to a large unmet need
The first dengue vaccine, Dengvaxia (CYD-TDV) developed by Sanofi Pasteur is registered in 14 countries in the Latin America and Asia Pacific region. CYD-TDV vaccine is a live recombinant tetravalent dengue vaccine that is indicated as a 3 dose series of 0/6/12 month schedule. There are around five other vaccine candidates under evaluation in clinical trials, comprising other live-attenuated vaccines as well as subunit, DNA and purified inactivated vaccine candidates of which Takedas TAK-003 and Butantan Institute vaccine candidates are being evaluated in phase 3 clinical trials currently.
The global dengue vaccine market is estimated to be valued at nearly US$ 250 Mn in 2017 and is expected to expand at a 17.5% CAGR over the forecast period (2017-2027). The global dengue vaccine market is projected to be valued at more than US$ 1250 Mn by 2027.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=1287933
Factors impacting the global dengue vaccine market
Growth of the global dengue vaccine market is mainly driven by rising burden of dengue fever in tropical regions, large unmet medical need for managing dengue burden, promising end stage vaccine pipeline, development of live attenuated tetravalent dengue vaccine, and expected local production of dengue vaccine in various countries. Other prominent factors driving revenue growth of the market are adoption/uptake of dengue vaccine by various countries in dengue endemic regions of Latin America and Asia Pacific and increased governmental interest to incorporate the vaccine in public immunisation programmes across various countries.
However, supply side infrastructure bottlenecks such as surveillance system, standardised diagnostics practice, and cold chain systems for storage of vaccine in resource constrained countries are the factors hampering the growth of the global dengue vaccine market.
Companies engaged in the development of dengue vaccine are employing strategies to incorporate dengue vaccine in public immunisation programmes and vaccines in clinical stage development are being tested for safety and efficacy in all age groups and different transmission settings.
Browse more details @ http://www.researchmoz.us/dengue-vaccine-market-contribution-of-ngos-for-better-vaccine-access-expected-to-drive-the-market-in-lower-income-countries-global-industry-analysis-and-opportunity-assessment-2017-2027-report.html
Table Of Content
1. Executive Summary
2. Market Introduction
2.1. Market Taxonomy
3. Global Dengue Vaccine Market Analysis Scenario
3.1. Market Size (US$ Mn) and Forecast
3.1.1. Market Size and Y-o-Y Growth
3.2.2. Absolute $ Opportunity
3.2. Market Overview
4. Market Dynamics and USPs
4.1. Macro-economic Factors
4.2. Drivers
4.2.1. Supply Side
4.2.2. Demand Side
4.3. Restraints
4.4. Opportunity
4.5. Trends
4.6. Dengue Vaccine Research Pipeline Analysis
4.7. Global Dengue Vaccine Market: Funding Scenario
4.8. Global Dengue Vaccine Market: Dengue Epidemiology Analysis
4.9. Global Dengue Vaccine Market: Dengvaxia SWOT
4.10. Global Dengue Vaccine Market: Dengvaxia Promotional Activities
4.11.Global Dengue Vaccine Market: Dengvaxia Sales Channel Strategy
4.12. Global Dengue Vaccine Market: Dengvaxia Tier-Pricing by Region
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
No comments:
Post a Comment